At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Dasatinib for Breast Cancer and Metastasis. Completed, enrolled 55 participants across 10 sites in 4 countries.
Detailed Summary
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Metastasis
CountriesFrance, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartDec 2006
Primary CompletionSep 2008
TodayJul 2026
First PostedSep 4, 2006
Enrollment StartDec 1, 2006
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.8 years ago
Interventions
Dasatinibdrug
Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months)
Dasatinibdrug
Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)